1. Home
  2. LXRX vs GSBD Comparison

LXRX vs GSBD Comparison

Compare LXRX & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LXRX

Lexicon Pharmaceuticals Inc.

HOLD

Current Price

$1.60

Market Cap

996.7M

Sector

Health Care

ML Signal

HOLD

Logo Goldman Sachs BDC Inc.

GSBD

Goldman Sachs BDC Inc.

HOLD

Current Price

$8.61

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXRX
GSBD
Founded
1995
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
996.7M
1.1B
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
LXRX
GSBD
Price
$1.60
$8.61
Analyst Decision
Buy
Sell
Analyst Count
6
5
Target Price
$4.55
★ $8.94
AVG Volume (30 Days)
★ 2.6M
772.6K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
★ 15.69%
EPS Growth
77.78
★ 87.27
EPS
N/A
★ 0.09
Revenue
★ $49,803,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$94.61
Revenue Growth
★ 60.24
N/A
52 Week Low
$1.10
$8.36
52 Week High
$2.68
$10.38

Technical Indicators

Market Signals
Indicator
LXRX
GSBD
Relative Strength Index (RSI) 34.71 34.83
Support Level $1.50 $8.42
Resistance Level $1.81 $9.11
Average True Range (ATR) 0.07 0.20
MACD -0.00 -0.02
Stochastic Oscillator 27.20 17.54

Price Performance

Historical Comparison
LXRX
GSBD

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

Share on Social Networks: